The FDA began accepting applications for an expedited investigational new drug (IND) pilot program designed to speed early human testing, incorporating public feedback into the qualification criteria. The agency framed the effort as part of “Operation Trialblazer,” and its approach focuses on narrowing the path from preclinical work to IND readiness. Key FDA leadership — including permanent directors Karim Mikhail and Michael Davis — said the program will prioritize sponsors and settings that meet the pilot’s requirements, aiming to reduce time spent in early-stage administrative bottlenecks. Industry has been watching the pilot for signs that the FDA is willing to modernize trial initiation timelines for promising candidates, especially where the evidence package is strong but could benefit from faster engagement with clinical investigators.